Novo Nordisk licenses experimental GLP-1 obesity pill from Hengrui for up to $2.6 billion
Novo Nordisk will pay up to $2.6 billion to license HRS-1596, an experimental oral obesity drug from China's Jiangsu Hengrui Pharmaceuticals, marking the company's second major deal since a key investor meeting.
